CAR T-cell Therapy in MM: Coordination of Care Between Our Center and Yours

Target Audience

This activity will provide continuing medical education (CME) that addresses identified knowledge and practice gaps among community-based hematologist/oncologist clinicians (MDs, APPs and nurses).

Program Overview

This small-group workshop, CAR T-Cell Therapy in Multiple Myeloma—Coordination of Care Between Our Center and Yours, will provide community hematologist/oncologists with a comprehensive overview of US Food and Drug Administration (FDA)-approved CAR T-cell therapies for RRMM, including current National Comprehensive Cancer Network Guidelines® recommendations and comparative efficacy and safety data. A faculty expert on MM from a local CAR T treatment center will outline practical strategies for identifying eligible patients earlier in their disease course, considering key patient- and disease-specific factors. Participants will explore the full CAR T care pathway, with an emphasis on overcoming barriers. The session will also address recognition and management of both short- and long-term treatment-emergent AEs and the importance of ongoing communication between community practices and treatment centers. Learner questions gathered during and after the session will shape content for follow-up educational reinforcement videos.

Educational Objectives 

After completing this activity, the participant should be better able to:

• Identify patients with RRMM early in the treatment course who may be eligible for referral to CAR T-cell therapy
• Compare the efficacy and safety profiles of FDA-approved CAR T-cell therapy
• Describe the monitoring, mitigation, and management strategies for potential short- and long-term adverse events associated with CAR T-cell therapy

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Integritas Contact Information

For more information about the approval of this program, please contact Integritas at info@exchangecme.com. 

Instructions to Receive Credit

In order to receive credit for this activity, the participant must:

1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
2. Complete the Preactivity Questions.
3. Review the activity content.
4. Achieve a grade of at least 70% on the Postactivity Test Questions and complete the Evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas.  All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.  

All relevant financial relationships have been mitigated. 

The faculty have the following relevant financial relationships with ineligible companies:

Krina K. Patel, MD, MSc

• Consulting Fees: AbbVie Inc., AstraZeneca, Bristol Myers Squibb, Celgene, Johnson and Johnson, Kite, Legend Biotech, Merck, Oncopeptides, Oricel, and Pfizer Inc. 
• Advisory Board: Novartis Pharmaceuticals and Novartis
• Contracted Research: AbbVie Inc., Bristol Myers Squibb, Celgene, Johnson and Johnson, and Takeda

The Integritas planners and managers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.